Induction of neutralising antibodies and cellular immune responses against SARS coronavirus by recombinant measles viruses
Identifieur interne : 003494 ( Main/Exploration ); précédent : 003493; suivant : 003495Induction of neutralising antibodies and cellular immune responses against SARS coronavirus by recombinant measles viruses
Auteurs : Matthias Liniger [Suisse] ; Armando Zuniga [Suisse] ; Azaibi Tamin [États-Unis] ; Teldja N. Azzouz-Morin [Suisse] ; Marlyse Knuchel [Suisse] ; Rene R. Marty [Suisse] ; Marian Wiegand [Suisse] ; Sara Weibel [Suisse] ; David Kelvin [Canada] ; Paul A. Rota [États-Unis] ; Hussein Y. Naim [Suisse]Source :
- Vaccine [ 0264-410X ] ; 2008.
Descripteurs français
- KwdFr :
- Animal génétiquement modifié, Animaux, Glycoprotéine de spicule des coronavirus, Glycoprotéines membranaires (génétique), Glycoprotéines membranaires (immunologie), Protéines de l'enveloppe virale (immunologie), Protéines nucléocapside (génétique), Souris, Syndrome respiratoire aigu sévère (), Syndrome respiratoire aigu sévère (immunologie), Tests de neutralisation, Vaccin contre la rougeole (administration et posologie), Vaccin contre la rougeole (génétique), Vaccin contre la rougeole (immunologie), Vaccins antiviraux (), Vaccins antiviraux (administration et posologie), Vaccins antiviraux (génétique), Vaccins antiviraux (immunologie), Vaccins synthétiques (administration et posologie), Vaccins synthétiques (immunologie), Vecteurs génétiques (), Virus de la rougeole (métabolisme), Virus de la rougeole (physiologie), Virus du SRAS (génétique), Virus du SRAS (immunologie), Virus du SRAS (métabolisme).
- MESH :
- administration et posologie : Vaccin contre la rougeole, Vaccins antiviraux, Vaccins synthétiques.
- génétique : Glycoprotéines membranaires, Protéines nucléocapside, Vaccin contre la rougeole, Vaccins antiviraux, Virus du SRAS.
- immunologie : Glycoprotéines membranaires, Protéines de l'enveloppe virale, Syndrome respiratoire aigu sévère, Vaccin contre la rougeole, Vaccins antiviraux, Vaccins synthétiques, Virus du SRAS.
- métabolisme : Virus de la rougeole, Virus du SRAS.
- physiologie : Virus de la rougeole.
- Pascal (Inist)
- Animal génétiquement modifié, Animaux, Glycoprotéine de spicule des coronavirus, Souris, Syndrome respiratoire aigu sévère, Tests de neutralisation, Vaccins antiviraux, Vecteurs génétiques, Virus syndrome respiratoire aigu sévère, Virus rougeole, Anticorps neutralisant, Immunité humorale, Réponse immune, Immunité cellulaire, Vaccin, Vecteur, Rougeole.
- Wicri :
- topic : Vaccin.
English descriptors
- KwdEn :
- Animals, Animals, Genetically Modified, Cellular immunity, Genetic Vectors (chemistry), Humoral immunity, Immune response, Measles, Measles Vaccine (administration & dosage), Measles Vaccine (genetics), Measles Vaccine (immunology), Measles virus, Measles virus (metabolism), Measles virus (physiology), Membrane Glycoproteins (genetics), Membrane Glycoproteins (immunology), Mice, Neutralization Tests, Neutralizing antibody, Nucleocapsid Proteins (genetics), SARS Virus (genetics), SARS Virus (immunology), SARS Virus (metabolism), Severe Acute Respiratory Syndrome (immunology), Severe Acute Respiratory Syndrome (prevention & control), Severe acute respiratory syndrome virus, Spike Glycoprotein, Coronavirus, Vaccine, Vaccines, Synthetic (administration & dosage), Vaccines, Synthetic (immunology), Vector, Viral Envelope Proteins (immunology), Viral Vaccines (administration & dosage), Viral Vaccines (chemistry), Viral Vaccines (genetics), Viral Vaccines (immunology).
- MESH :
- chemical , administration & dosage : Measles Vaccine, Vaccines, Synthetic, Viral Vaccines.
- chemistry : Genetic Vectors, Viral Vaccines.
- chemical , genetics : Measles Vaccine, Membrane Glycoproteins, Nucleocapsid Proteins, SARS Virus, Viral Vaccines.
- chemical , immunology : Measles Vaccine, Membrane Glycoproteins, SARS Virus, Severe Acute Respiratory Syndrome, Vaccines, Synthetic, Viral Envelope Proteins, Viral Vaccines.
- metabolism : Measles virus, SARS Virus.
- physiology : Measles virus.
- prevention & control : Severe Acute Respiratory Syndrome.
- Animals, Animals, Genetically Modified, Mice, Neutralization Tests, Spike Glycoprotein, Coronavirus.
Abstract
Live attenuated recombinant measles viruses (rMV) expressing a codon-optimised spike glycoprotein (S) or nucleocapsid protein (N) of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) were generated (rMV-S and rMV-N). Both recombinant viruses stably expressed the corresponding SARS-CoV proteins, grew to similar end titres as the parental strain and induced high antibody titres against MV and the vectored SARS-CoV antigens (S and N) in transgenic mice susceptible to measles infection. The antibodies induced by rMV-S had a high neutralising effect on SARS-CoV as well as on MV. Moreover, significant N-specific cellular immune responses were measured by IFN-γ ELISPOT assays. The pre-existence of anti-MV antibodies induced by the initial immunisation dose did not inhibit boost of anti-S and anti-N antibodies. Immunisations comprising a mixture of rMV-S and rMV-N induced immune responses similar in magnitude to that of vaccine components administered separately. These data support the suitability of MV as a bivalent candidate vaccine vector against MV and emerging viruses such as SARS-CoV.
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000293
- to stream PascalFrancis, to step Curation: 000695
- to stream PascalFrancis, to step Checkpoint: 000274
- to stream Main, to step Merge: 003600
- to stream PubMed, to step Corpus: 001B88
- to stream PubMed, to step Curation: 001B88
- to stream PubMed, to step Checkpoint: 001B09
- to stream Ncbi, to step Merge: 001C04
- to stream Ncbi, to step Curation: 001C04
- to stream Ncbi, to step Checkpoint: 001C04
- to stream Main, to step Merge: 003173
- to stream Main, to step Curation: 003494
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Induction of neutralising antibodies and cellular immune responses against SARS coronavirus by recombinant measles viruses</title><author><name sortKey="Liniger, Matthias" sort="Liniger, Matthias" uniqKey="Liniger M" first="Matthias" last="Liniger">Matthias Liniger</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Berna Biotech (a Crucell Company), Rehhagstrasse 79</s1><s2>3018 Bern</s2><s3>CHE</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>11 aut.</sZ></inist:fA14><country>Suisse</country><placeName><settlement type="city">Berne</settlement><region type="région" nuts="3">Canton de Berne</region></placeName></affiliation></author><author><name sortKey="Zuniga, Armando" sort="Zuniga, Armando" uniqKey="Zuniga A" first="Armando" last="Zuniga">Armando Zuniga</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Berna Biotech (a Crucell Company), Rehhagstrasse 79</s1><s2>3018 Bern</s2><s3>CHE</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>11 aut.</sZ></inist:fA14><country>Suisse</country><placeName><settlement type="city">Berne</settlement><region type="région" nuts="3">Canton de Berne</region></placeName></affiliation></author><author><name sortKey="Tamin, Azaibi" sort="Tamin, Azaibi" uniqKey="Tamin A" first="Azaibi" last="Tamin">Azaibi Tamin</name><affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Centers for Disease Control and Prevention, 1600 Clifton Road</s1><s2>Atlanta, GA 30333</s2><s3>USA</s3><sZ>3 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Géorgie (États-Unis)</region></placeName></affiliation></author><author><name sortKey="Azzouz Morin, Teldja N" sort="Azzouz Morin, Teldja N" uniqKey="Azzouz Morin T" first="Teldja N." last="Azzouz-Morin">Teldja N. Azzouz-Morin</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Berna Biotech (a Crucell Company), Rehhagstrasse 79</s1><s2>3018 Bern</s2><s3>CHE</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>11 aut.</sZ></inist:fA14><country>Suisse</country><placeName><settlement type="city">Berne</settlement><region type="région" nuts="3">Canton de Berne</region></placeName></affiliation></author><author><name sortKey="Knuchel, Marlyse" sort="Knuchel, Marlyse" uniqKey="Knuchel M" first="Marlyse" last="Knuchel">Marlyse Knuchel</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Berna Biotech (a Crucell Company), Rehhagstrasse 79</s1><s2>3018 Bern</s2><s3>CHE</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>11 aut.</sZ></inist:fA14><country>Suisse</country><placeName><settlement type="city">Berne</settlement><region type="région" nuts="3">Canton de Berne</region></placeName></affiliation></author><author><name sortKey="Marty, Rene R" sort="Marty, Rene R" uniqKey="Marty R" first="Rene R." last="Marty">Rene R. Marty</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Berna Biotech (a Crucell Company), Rehhagstrasse 79</s1><s2>3018 Bern</s2><s3>CHE</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>11 aut.</sZ></inist:fA14><country>Suisse</country><placeName><settlement type="city">Berne</settlement><region type="région" nuts="3">Canton de Berne</region></placeName></affiliation></author><author><name sortKey="Wiegand, Marian" sort="Wiegand, Marian" uniqKey="Wiegand M" first="Marian" last="Wiegand">Marian Wiegand</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Berna Biotech (a Crucell Company), Rehhagstrasse 79</s1><s2>3018 Bern</s2><s3>CHE</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>11 aut.</sZ></inist:fA14><country>Suisse</country><placeName><settlement type="city">Berne</settlement><region type="région" nuts="3">Canton de Berne</region></placeName></affiliation></author><author><name sortKey="Weibel, Sara" sort="Weibel, Sara" uniqKey="Weibel S" first="Sara" last="Weibel">Sara Weibel</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Berna Biotech (a Crucell Company), Rehhagstrasse 79</s1><s2>3018 Bern</s2><s3>CHE</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>11 aut.</sZ></inist:fA14><country>Suisse</country><placeName><settlement type="city">Berne</settlement><region type="région" nuts="3">Canton de Berne</region></placeName></affiliation></author><author><name sortKey="Kelvin, David" sort="Kelvin, David" uniqKey="Kelvin D" first="David" last="Kelvin">David Kelvin</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>University Health Network, 610 University Avenue</s1><s2>Toronto</s2><s3>CAN</s3><sZ>9 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Toronto</wicri:noRegion></affiliation></author><author><name sortKey="Rota, Paul A" sort="Rota, Paul A" uniqKey="Rota P" first="Paul A." last="Rota">Paul A. Rota</name><affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Centers for Disease Control and Prevention, 1600 Clifton Road</s1><s2>Atlanta, GA 30333</s2><s3>USA</s3><sZ>3 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Géorgie (États-Unis)</region></placeName></affiliation></author><author><name sortKey="Naim, Hussein Y" sort="Naim, Hussein Y" uniqKey="Naim H" first="Hussein Y." last="Naim">Hussein Y. Naim</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Berna Biotech (a Crucell Company), Rehhagstrasse 79</s1><s2>3018 Bern</s2><s3>CHE</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>11 aut.</sZ></inist:fA14><country>Suisse</country><placeName><settlement type="city">Berne</settlement><region type="région" nuts="3">Canton de Berne</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">08-0220446</idno><date when="2008">2008</date><idno type="stanalyst">PASCAL 08-0220446 INIST</idno><idno type="RBID">Pascal:08-0220446</idno><idno type="wicri:Area/PascalFrancis/Corpus">000293</idno><idno type="wicri:Area/PascalFrancis/Curation">000695</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000274</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000274</idno><idno type="wicri:doubleKey">0264-410X:2008:Liniger M:induction:of:neutralising</idno><idno type="wicri:Area/Main/Merge">003600</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:18346823</idno><idno type="wicri:Area/PubMed/Corpus">001B88</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001B88</idno><idno type="wicri:Area/PubMed/Curation">001B88</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001B88</idno><idno type="wicri:Area/PubMed/Checkpoint">001B09</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001B09</idno><idno type="wicri:Area/Ncbi/Merge">001C04</idno><idno type="wicri:Area/Ncbi/Curation">001C04</idno><idno type="wicri:Area/Ncbi/Checkpoint">001C04</idno><idno type="wicri:doubleKey">0264-410X:2008:Liniger M:induction:of:neutralising</idno><idno type="wicri:Area/Main/Merge">003173</idno><idno type="wicri:Area/Main/Curation">003494</idno><idno type="wicri:Area/Main/Exploration">003494</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Induction of neutralising antibodies and cellular immune responses against SARS coronavirus by recombinant measles viruses</title><author><name sortKey="Liniger, Matthias" sort="Liniger, Matthias" uniqKey="Liniger M" first="Matthias" last="Liniger">Matthias Liniger</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Berna Biotech (a Crucell Company), Rehhagstrasse 79</s1><s2>3018 Bern</s2><s3>CHE</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>11 aut.</sZ></inist:fA14><country>Suisse</country><placeName><settlement type="city">Berne</settlement><region type="région" nuts="3">Canton de Berne</region></placeName></affiliation></author><author><name sortKey="Zuniga, Armando" sort="Zuniga, Armando" uniqKey="Zuniga A" first="Armando" last="Zuniga">Armando Zuniga</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Berna Biotech (a Crucell Company), Rehhagstrasse 79</s1><s2>3018 Bern</s2><s3>CHE</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>11 aut.</sZ></inist:fA14><country>Suisse</country><placeName><settlement type="city">Berne</settlement><region type="région" nuts="3">Canton de Berne</region></placeName></affiliation></author><author><name sortKey="Tamin, Azaibi" sort="Tamin, Azaibi" uniqKey="Tamin A" first="Azaibi" last="Tamin">Azaibi Tamin</name><affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Centers for Disease Control and Prevention, 1600 Clifton Road</s1><s2>Atlanta, GA 30333</s2><s3>USA</s3><sZ>3 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Géorgie (États-Unis)</region></placeName></affiliation></author><author><name sortKey="Azzouz Morin, Teldja N" sort="Azzouz Morin, Teldja N" uniqKey="Azzouz Morin T" first="Teldja N." last="Azzouz-Morin">Teldja N. Azzouz-Morin</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Berna Biotech (a Crucell Company), Rehhagstrasse 79</s1><s2>3018 Bern</s2><s3>CHE</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>11 aut.</sZ></inist:fA14><country>Suisse</country><placeName><settlement type="city">Berne</settlement><region type="région" nuts="3">Canton de Berne</region></placeName></affiliation></author><author><name sortKey="Knuchel, Marlyse" sort="Knuchel, Marlyse" uniqKey="Knuchel M" first="Marlyse" last="Knuchel">Marlyse Knuchel</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Berna Biotech (a Crucell Company), Rehhagstrasse 79</s1><s2>3018 Bern</s2><s3>CHE</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>11 aut.</sZ></inist:fA14><country>Suisse</country><placeName><settlement type="city">Berne</settlement><region type="région" nuts="3">Canton de Berne</region></placeName></affiliation></author><author><name sortKey="Marty, Rene R" sort="Marty, Rene R" uniqKey="Marty R" first="Rene R." last="Marty">Rene R. Marty</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Berna Biotech (a Crucell Company), Rehhagstrasse 79</s1><s2>3018 Bern</s2><s3>CHE</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>11 aut.</sZ></inist:fA14><country>Suisse</country><placeName><settlement type="city">Berne</settlement><region type="région" nuts="3">Canton de Berne</region></placeName></affiliation></author><author><name sortKey="Wiegand, Marian" sort="Wiegand, Marian" uniqKey="Wiegand M" first="Marian" last="Wiegand">Marian Wiegand</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Berna Biotech (a Crucell Company), Rehhagstrasse 79</s1><s2>3018 Bern</s2><s3>CHE</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>11 aut.</sZ></inist:fA14><country>Suisse</country><placeName><settlement type="city">Berne</settlement><region type="région" nuts="3">Canton de Berne</region></placeName></affiliation></author><author><name sortKey="Weibel, Sara" sort="Weibel, Sara" uniqKey="Weibel S" first="Sara" last="Weibel">Sara Weibel</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Berna Biotech (a Crucell Company), Rehhagstrasse 79</s1><s2>3018 Bern</s2><s3>CHE</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>11 aut.</sZ></inist:fA14><country>Suisse</country><placeName><settlement type="city">Berne</settlement><region type="région" nuts="3">Canton de Berne</region></placeName></affiliation></author><author><name sortKey="Kelvin, David" sort="Kelvin, David" uniqKey="Kelvin D" first="David" last="Kelvin">David Kelvin</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>University Health Network, 610 University Avenue</s1><s2>Toronto</s2><s3>CAN</s3><sZ>9 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Toronto</wicri:noRegion></affiliation></author><author><name sortKey="Rota, Paul A" sort="Rota, Paul A" uniqKey="Rota P" first="Paul A." last="Rota">Paul A. Rota</name><affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Centers for Disease Control and Prevention, 1600 Clifton Road</s1><s2>Atlanta, GA 30333</s2><s3>USA</s3><sZ>3 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Géorgie (États-Unis)</region></placeName></affiliation></author><author><name sortKey="Naim, Hussein Y" sort="Naim, Hussein Y" uniqKey="Naim H" first="Hussein Y." last="Naim">Hussein Y. Naim</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Berna Biotech (a Crucell Company), Rehhagstrasse 79</s1><s2>3018 Bern</s2><s3>CHE</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>11 aut.</sZ></inist:fA14><country>Suisse</country><placeName><settlement type="city">Berne</settlement><region type="région" nuts="3">Canton de Berne</region></placeName></affiliation></author></analytic><series><title level="j" type="main">Vaccine</title><title level="j" type="abbreviated">Vaccine</title><idno type="ISSN">0264-410X</idno><imprint><date when="2008">2008</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Vaccine</title><title level="j" type="abbreviated">Vaccine</title><idno type="ISSN">0264-410X</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Animals, Genetically Modified</term><term>Cellular immunity</term><term>Genetic Vectors (chemistry)</term><term>Humoral immunity</term><term>Immune response</term><term>Measles</term><term>Measles Vaccine (administration & dosage)</term><term>Measles Vaccine (genetics)</term><term>Measles Vaccine (immunology)</term><term>Measles virus</term><term>Measles virus (metabolism)</term><term>Measles virus (physiology)</term><term>Membrane Glycoproteins (genetics)</term><term>Membrane Glycoproteins (immunology)</term><term>Mice</term><term>Neutralization Tests</term><term>Neutralizing antibody</term><term>Nucleocapsid Proteins (genetics)</term><term>SARS Virus (genetics)</term><term>SARS Virus (immunology)</term><term>SARS Virus (metabolism)</term><term>Severe Acute Respiratory Syndrome (immunology)</term><term>Severe Acute Respiratory Syndrome (prevention & control)</term><term>Severe acute respiratory syndrome virus</term><term>Spike Glycoprotein, Coronavirus</term><term>Vaccine</term><term>Vaccines, Synthetic (administration & dosage)</term><term>Vaccines, Synthetic (immunology)</term><term>Vector</term><term>Viral Envelope Proteins (immunology)</term><term>Viral Vaccines (administration & dosage)</term><term>Viral Vaccines (chemistry)</term><term>Viral Vaccines (genetics)</term><term>Viral Vaccines (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animal génétiquement modifié</term><term>Animaux</term><term>Glycoprotéine de spicule des coronavirus</term><term>Glycoprotéines membranaires (génétique)</term><term>Glycoprotéines membranaires (immunologie)</term><term>Protéines de l'enveloppe virale (immunologie)</term><term>Protéines nucléocapside (génétique)</term><term>Souris</term><term>Syndrome respiratoire aigu sévère ()</term><term>Syndrome respiratoire aigu sévère (immunologie)</term><term>Tests de neutralisation</term><term>Vaccin contre la rougeole (administration et posologie)</term><term>Vaccin contre la rougeole (génétique)</term><term>Vaccin contre la rougeole (immunologie)</term><term>Vaccins antiviraux ()</term><term>Vaccins antiviraux (administration et posologie)</term><term>Vaccins antiviraux (génétique)</term><term>Vaccins antiviraux (immunologie)</term><term>Vaccins synthétiques (administration et posologie)</term><term>Vaccins synthétiques (immunologie)</term><term>Vecteurs génétiques ()</term><term>Virus de la rougeole (métabolisme)</term><term>Virus de la rougeole (physiologie)</term><term>Virus du SRAS (génétique)</term><term>Virus du SRAS (immunologie)</term><term>Virus du SRAS (métabolisme)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Measles Vaccine</term><term>Vaccines, Synthetic</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccin contre la rougeole</term><term>Vaccins antiviraux</term><term>Vaccins synthétiques</term></keywords><keywords scheme="MESH" qualifier="chemistry" xml:lang="en"><term>Genetic Vectors</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Measles Vaccine</term><term>Membrane Glycoproteins</term><term>Nucleocapsid Proteins</term><term>SARS Virus</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Glycoprotéines membranaires</term><term>Protéines nucléocapside</term><term>Vaccin contre la rougeole</term><term>Vaccins antiviraux</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Glycoprotéines membranaires</term><term>Protéines de l'enveloppe virale</term><term>Syndrome respiratoire aigu sévère</term><term>Vaccin contre la rougeole</term><term>Vaccins antiviraux</term><term>Vaccins synthétiques</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Measles Vaccine</term><term>Membrane Glycoproteins</term><term>SARS Virus</term><term>Severe Acute Respiratory Syndrome</term><term>Vaccines, Synthetic</term><term>Viral Envelope Proteins</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Measles virus</term><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Virus de la rougeole</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Virus de la rougeole</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Measles virus</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Animals, Genetically Modified</term><term>Mice</term><term>Neutralization Tests</term><term>Spike Glycoprotein, Coronavirus</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Animal génétiquement modifié</term><term>Animaux</term><term>Glycoprotéine de spicule des coronavirus</term><term>Souris</term><term>Syndrome respiratoire aigu sévère</term><term>Tests de neutralisation</term><term>Vaccins antiviraux</term><term>Vecteurs génétiques</term><term>Virus syndrome respiratoire aigu sévère</term><term>Virus rougeole</term><term>Anticorps neutralisant</term><term>Immunité humorale</term><term>Réponse immune</term><term>Immunité cellulaire</term><term>Vaccin</term><term>Vecteur</term><term>Rougeole</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Vaccin</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Live attenuated recombinant measles viruses (rMV) expressing a codon-optimised spike glycoprotein (S) or nucleocapsid protein (N) of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) were generated (rMV-S and rMV-N). Both recombinant viruses stably expressed the corresponding SARS-CoV proteins, grew to similar end titres as the parental strain and induced high antibody titres against MV and the vectored SARS-CoV antigens (S and N) in transgenic mice susceptible to measles infection. The antibodies induced by rMV-S had a high neutralising effect on SARS-CoV as well as on MV. Moreover, significant N-specific cellular immune responses were measured by IFN-γ ELISPOT assays. The pre-existence of anti-MV antibodies induced by the initial immunisation dose did not inhibit boost of anti-S and anti-N antibodies. Immunisations comprising a mixture of rMV-S and rMV-N induced immune responses similar in magnitude to that of vaccine components administered separately. These data support the suitability of MV as a bivalent candidate vaccine vector against MV and emerging viruses such as SARS-CoV.</div></front></TEI><affiliations><list><country><li>Canada</li><li>Suisse</li><li>États-Unis</li></country><region><li>Canton de Berne</li><li>Géorgie (États-Unis)</li></region><settlement><li>Berne</li></settlement></list><tree><country name="Suisse"><region name="Canton de Berne"><name sortKey="Liniger, Matthias" sort="Liniger, Matthias" uniqKey="Liniger M" first="Matthias" last="Liniger">Matthias Liniger</name></region><name sortKey="Azzouz Morin, Teldja N" sort="Azzouz Morin, Teldja N" uniqKey="Azzouz Morin T" first="Teldja N." last="Azzouz-Morin">Teldja N. Azzouz-Morin</name><name sortKey="Knuchel, Marlyse" sort="Knuchel, Marlyse" uniqKey="Knuchel M" first="Marlyse" last="Knuchel">Marlyse Knuchel</name><name sortKey="Marty, Rene R" sort="Marty, Rene R" uniqKey="Marty R" first="Rene R." last="Marty">Rene R. Marty</name><name sortKey="Naim, Hussein Y" sort="Naim, Hussein Y" uniqKey="Naim H" first="Hussein Y." last="Naim">Hussein Y. Naim</name><name sortKey="Weibel, Sara" sort="Weibel, Sara" uniqKey="Weibel S" first="Sara" last="Weibel">Sara Weibel</name><name sortKey="Wiegand, Marian" sort="Wiegand, Marian" uniqKey="Wiegand M" first="Marian" last="Wiegand">Marian Wiegand</name><name sortKey="Zuniga, Armando" sort="Zuniga, Armando" uniqKey="Zuniga A" first="Armando" last="Zuniga">Armando Zuniga</name></country><country name="États-Unis"><region name="Géorgie (États-Unis)"><name sortKey="Tamin, Azaibi" sort="Tamin, Azaibi" uniqKey="Tamin A" first="Azaibi" last="Tamin">Azaibi Tamin</name></region><name sortKey="Rota, Paul A" sort="Rota, Paul A" uniqKey="Rota P" first="Paul A." last="Rota">Paul A. Rota</name></country><country name="Canada"><noRegion><name sortKey="Kelvin, David" sort="Kelvin, David" uniqKey="Kelvin D" first="David" last="Kelvin">David Kelvin</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003494 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003494 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:08-0220446
|texte= Induction of neutralising antibodies and cellular immune responses against SARS coronavirus by recombinant measles viruses
}}
| This area was generated with Dilib version V0.6.33. |  |